top of page

【Industry News】Vertex plunks down $950M for stem cell player Semma Therapeutics

View Source:https://www.fiercebiotech.com/biotech/vertex-plunks-down-950m-for-stem-cell-player-semma-therapeutics

Sep 3, 2019

Vertex Pharmaceuticals is jumping into diabetes. The cystic fibrosis specialist is snapping up Semma Therapeutics and its stem cell-based diabetes treatments for $950 million in an all-cash deal slated to close in the fourth quarter. 

Douglas Melton, Ph.D., founded Semma in 2014 to work on a potential cure for Type 1 diabetes. His idea was turning undifferentiated pluripotent stem cells into insulin-producing pancreatic beta cells that could be transplanted into patients. The company unveiled itself the following year with a $44 million series A and a partnership with Novartis, chosen over other diabetes-focused suitors for its expertise in cell therapy. 

The biotech went on to raise a head-turning $114 million series B round in 2017 and hired Bastiano Sanna as its CEO. Sanna was formerly the chief operating officer at Magenta Therapeutics and global head of stem cell transplant programs at Novartis, where he helped oversee the Big Pharma’s CAR-T cell therapy development. 

This website is for informational purposes only and does not constitute an offer to sell, a solicitation to buy, or a recommendation for any security; nor does it constitute an offer to provide investment advisory or other services by Viva Ventures Biotech Fund or any of our affiliates. Nothing contained on the website constitutes investment advice or offers any opinion with respect to the suitability of any security, and the views expressed on this website should not be taken as advice to buy, sell, or hold any security or as an endorsement of any security or company. In preparing the information contained in this website, Viva Ventures Biotech has not taken into account the investment needs, objectives, and financial circumstances of any particular investor, and investments and companies referenced may not be suitable for all investors. Any views expressed on this website by Viva Ventures biotech were prepared based upon information, believed to be reliable, available to it at the time such views were written. Viva Ventures Biotech makes no guarantees as to their accuracy or completeness. All information is subject to change and may quickly become unreliable for various reasons, including changes in market conditions or economic circumstances. By accessing this website, the reader agrees that he/she not copy, reproduce, republish, upload, post, transmit, alter, or distribute in any way material from this website in any manner inconsistent with the purposes for which it is offered without the prior written consent of Viva Ventures Biotech.

bottom of page